Mutabilis joins European project supporting antiobiotics research

France's Mutabilis, a spinout from INSERM focused on new antibiotics, has announced it is participating in the European ENABLE project.

With an overall budget of more than 88 million euros ($104 million) for the period from 2014 to 2020, the project is aimed at combating infections caused by Gram-negative bacteria.

Under the project, 75% of expenditure incurred up to Phase I trials are reimbursed, throughout the period of collaboration.

In addition to this financial support, Mutabilis will have access to the research platform’s technical resources and will benefit from its specialists’ expertise.

Mutabilis is working on dabocillins, a family of innovative compounds that specifically target PBPs (penicillin-binding proteins).